Chengdu huasun technology group Inc., LTD. (000790)
- 3.62
- -0.05-1.36%
Chengdu huasun technology group Inc., LTD. (000790) News
Huashen Technology: 2026 Semi-Annual Performance Forecast
Huasun - Puesto 12 En La Lista De Las Principales Empresas De Tecnología Verde Del Mundo De TIME Para 2026
Stock A experienced significant fluctuations following the release of a major plan, with Hainan-related stocks rallying and HaiDe Co., Ltd. hitting the price limit.
Gelonghui, April 30 | Some Hainan-related stocks in the A-share market surged, among which Huashen Technology and Haide Stock hit the daily limit. Hainan Airlines approached the daily limit, while Luoniu Mountain, Haiqi Group, Hainan Ruiz, Hainan Development, Hainan Expressway, Haixia Stock, Shennong Seed Industry, and Caesar Travel also rose. In terms of news, the draft plan for the "15th Five-Year Plan" for Hainan International Tourism and Consumption Center was released for public consultation. The document mentioned fostering main players in space tourism, enriching space tourism products and business forms, implementing a negative list system for market access, and vigorously developing sports event economy.
Huashen Technology: First Quarter Report for 2026
Chengdu huasun technology group Inc., LTD.: Summary of the Annual Report for 2025
Chengdu huasun technology group Inc., LTD.: Annual Report 2025
Huashen Technology: 2025 Annual Performance Forecast
Huashen Technology (000790.SZ): Estimated loss of 270 million to 330 million yuan in 2025
Gelonghui, January 30th, Hua Shen Technology (000790.SZ) announced that it expects a net loss of 270 million to 330 million yuan for 2025, compared with a net loss of 6.6902 million yuan in the same period last year; non-recurring losses are expected to be between 245 million and 305 million yuan. Decline in operating performance: The company's core pharmaceutical products were affected by a reduction in listed procurement prices, leading to a decrease in revenue and gross profit; the company's continuous scaling back of its steel structure business resulted in reduced output value recognition and profit contribution; the newly invested Shandong Lingkai project incurred increased depreciation and amortization expenses from fixed asset conversion during the reporting period, failing to achieve expected returns and thus exacerbating operating losses.
Huashen Technology: An indicative announcement on the 2025 annual results forecast
Express News | Huashen Technology: Anticipated Net Profit Loss in 2025
Huashen Technology (000790.SZ): Plans to raise no more than 450 million yuan through a private placement to Yuanhong Bio.
Gelonghui, January 23rd: Huashen Technology (000790.SZ) announced that it plans to raise a total amount of no more than RMB 450 million (including this amount) through a private placement. The net proceeds after deducting issuance expenses will be entirely used for replenishing working capital and repaying loans. The target of this private placement of A-shares is Yuanhong Bio, which complies with the regulations set by the China Securities Regulatory Commission and other securities regulators allowing no more than thirty-five designated investors. The investor in this issuance will subscribe to the shares in cash. The investor in this issuance is an affiliate of the company.
Express News | Huashen Technology: Plans to Transfer the Marketing Authorization and Related Technologies for Smokeless Moxa Stick Products
Sichuan Huaxin (Group) Certified Public Accountants has been issued a warning letter for multiple violations in audit projects.
Blue Whale News, December 5th: Recently, the Sichuan Securities Regulatory Bureau issued an administrative regulatory measure decision, targeting Sichuan Huaxin (Group) Certified Public Accountants (Special General Partnership) and relevant personnel. The decision indicated that Sichuan Huaxin (Group) Certified Public Accountants encountered the following issues in the audit project of Chengdu Huashen Technology Group Co., Ltd.'s 2023 financial statements: I. Risk Assessment and Control Testing: First, it failed to combine the assessed risk of material misstatement at the financial statement level with the situation of its subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd. (hereinafter referred to as Tibet Kangyu), to specifically evaluate which types of revenue, revenue transactions, or assertions led...
The influenza outbreak has sparked market interest, prompting a surge in concept stocks. What is the underlying logic behind this phenomenon?
The current season is winter, and the drop in temperatures has led to increased viral activity, with a new wave of influenza making its return.
Targeting fields such as cell and gene therapy, and brain-computer interfaces! Shanghai's new pharmaceutical policies unleash multiple benefits, with innovative drugs and medical devices becoming the focal point.
In recent days, multiple brokerage research institutions have issued research reports expressing optimism about innovative medical devices and the innovative pharmaceuticals industry chain.
Huasun Energy Et New Time (Italie) Envisagent Une Coopération Stratégique Sur La Technologie HJT Et Les Applications BIPV En Europe
Huashen Technology: Report for the third quarter of 2025
Floating Solar Panels Market Growing at 26%+ CAGR to 2030 Driven by Renewable Energy Demand, Reports Mordor Intelligence
Significant Increase in Innovative Drug Revenue: The Pharmaceutical Industry Welcomes a New Logic
In the first half of 2025, the pharmaceutical industry has shaken off the gloom of the past few years, emerging as one of the brightest sectors in the capital market. The core logic behind this is the rise of innovative drugs in China. In the first half of this year, the transaction amount for outbound business development (BD) of Chinese innovative drugs exceeded the total for the entire previous year. Recent half-year reports have shown that domestic innovative drugs are experiencing rapid revenue growth. BeiGene, a leading innovative drug giant that has posted consecutive losses due to high R&D investments, has turned a profit for the first time in the first half of this year. The company's flagship product, Zanubrutinib (Brukinsa), has achieved significant results in the first half of the year.
Huashen Technology: 2025 Semi-Annual Report Summary